NahmMHHoffmannJW.Heteroantibody: phantom of the immunoassay. Clin Chem1990; 36: 829.
2.
SgourisJT.Limitations of the radioimmunoassay for hepatitis B antigen. N Engl J Med.1973; 288: 160–1.
3.
KrollMHElinRJ.Interference with clinical laboratory analyses. Clin Chem1994; 40: 1996–2005.
4.
ChapmanRS.Interference in immunoassay. Commun Lab Med.1992; 3: 49–55.
5.
GoslingJP.A decade of immunoassay development. Clin Chem1990; 36: 1408–27.
6.
BaudnerS.Measurement signal versus value in immunoassays for human plasma proteins. Scand J Clin Lab Invest Suppl1991; 205: 70–8.
7.
Anonymous. IFCC provisional recommendation on quality control in clinical chemistry. J Clin Chem Biochem1976; 14: 270.
8.
KefferJH.Preanalytical considerations in thyroid function testing. Clin Chem1996; 42: 125–34.
9.
CuckleHSWaldNJDensemJWRoystonP.The affect of smoking in pregnancy on maternal alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. Br J Obstet Gynaecol1991; 97: 1160–2.
10.
ButlerJ.Negative interference in immunoassays [Letter]. Clin Chem1995; 41: 481–2.
11.
SethJSturgeonCEllisA.Annual Report of the UK NEQAS for Peptide Hormones 1995. Edinburgh: UK NEQAS for Peptide Hormones, 1995.
12.
WoodPJDonovanSJChamberlainA.The influence of blood collection tube types on Immulite endocrine analyser results. In: Proceedings of the ACB National Meeting, Birmingham, UK, 1997: Abstract 54.
13.
NelsonJCWilcoxRBPandianMR.Dependence of free thyroxine estimates obtained with equilibrium tracer dialysis on the concentration of thyroxine binding proteins. Clin Chem1992; 38: 1294–300.
14.
BowieLJKirkpatrickPBDohnalJC.Thyroid function testing with the TDx: interference from endogenous fluophores. Clin Chem1987; 33: 1467.
15.
BloomJNHermanDCElinRJSilvaCARuddelMENussenblatRB.Intravenous fluorescein interference with clinical laboratory tests. Am J Ophthalmol1989; 108: 375–9.
16.
WeberTHKapyahoKITannerP.Endogenous interference in immunoassays in clinical chemistry. A review. Scand J Clin Lab Invest Suppl1990; 201: 77–82.
17.
SelbyCBarkerGALawsonN.The stability of seven commonly measured analytes in stored whole blood. In: Proceedings of the UK NEQAS Endocrinology Meeting, Cardiff, 1996: Abstract 13.
18.
DiverMJHughesJGHuttonJLWestCRHipkinLJ.The long term stability in whole blood of 14 commonly-requested hormone analytes. Ann Clin Biochem1994; 31: 561–5.
19.
HammerEJAstleyJP.Increase in serum testosterone following contact with blood cells. Ann Clin Biochem1985; 22: 539–40.
HashidaSNakagawaKImagawaMInoueSYoshitakeSIshikawaEUse of inorganic salts to minimise serum interference in a sandwich enzyme assay for growth hormone using Fab′ horse radish peroxidase conjugate. Clin Chim Acta1983; 135: 263–73.
22.
RatcliffeWACorrieJETDalzielAHMacPhersonJS.A general approach to the direct assay of progesterone in unextracted serum using a heterologous bridge system and a 125I radiolabel. Clin Chem1982; 28: 1314–8.
23.
WolfeLDAbruzzoJLHeimerR.Specificity of IgM antibodies to pooled human F(ab′)2 fragments. Immunol Commun1984; 13: 15–27.
24.
Labelling of protein antigens. In: HunterWMCorrieJET, eds. Immunoassays for Clinical Chemistry. Edinburgh: Churchill Livingstone, 1983: 263–315.
25.
WoodWGSokolowskiG.Tracer (125I) labelling. In: Radioimmunoassay Theory and Practice. A Handbook for Laboratory Personnel. Konstanz: Schnetztor Verlag, 1981: 95–114.
26.
Requirements for separation methods in immunoassay. In: HunterWMCorrieJET, eds. Immunoassays for Clinical Chemistry. Edinburgh: Churchill Livingstone, 1983: 135–207.
27.
EdwardsR.The development and use of PEG assisted second antibody as a separation technique in radioimmunoassay. In: HunterWMCorrieJET, eds. Immunoassays for Clinical Chemistry. Edinburgh: Churchill Livingstone; 1983: 139–46.
StockigtJRStevensVWhiteELBarlowJW. ‘Unbound analog’ radioimmunoassays for free thyroxine measure the albumin bound hormone fraction. Clin Chem1983; 29: 1408–10.
30.
KennedyDMSelbyCLawsonN.Measurement of urinary free Cortisol using the ACS:180 serum Cortisol assay. Proceedings of the XVI International Congress of Clinical Chemistry, London, 1996: 460.
31.
NelsonJCWeissRMWilcoxRB.Underestimates of serum free thyroxine (T4) concentrations by free T4 immunoassays. J Clin Endocrinol Metab1994; 79: 76–9.
32.
LahiriDKDavisDAdkinsMNurnbergerJIJrFactors that influence radioimmunoassay of plasma melatonin: a modified column procedure to eliminate interference. Biochem Med Metab Biol1993; 49: 36–50.
33.
NordernAGWJacksonRANordernLEGriffinAJBarnesMALittleJA.Misleading results from immunoassays of serum free thyroxine in the presence of rheumatoid factor. Clin Chem1997; 43: 957–62.
34.
HightonJHessianP.A solid phase enzyme immunoassay for C-reactive protein: clinical value and the effect of rheumatoid factor. J Immunol Methods1984; 68: 185–92.
35.
MullerWMierausRWholtmanD.Interferences of rheumatoid factor with nephelometric CRP determination. J Immunol Methods1985; 80: 77–90.
O'FarrellyCPriceRMcGillivrayAJFernandesL.IgA rheumatoid factor and IgG dietary protein antibodies are associated in rheumatoid arthritis. Immunol Invest1989; 18: 753–64.
38.
EssinkAWArkesteijnGJNotermanS.Interference in the sandwich enzyme-linked immunosorbent assay (ELISA). J Immunol Methods1985; 80: 91–6.
CollinsAM.Xenogeneric antibodies and atopic disease. Lancet1988; i: 734–7.
41.
MayCDRemigioLFeldmanJBockSACarrRI.A study of serum antibodies to isolated milk proteins and ovalbumin in infants and children. Clin Allergy1977; 7: 583–95.
42.
LarssonAWejakerPEForsbergPOLindahlT.Chicken antibodies: a tool to avoid interference from complement activation in ELISA. J Immunol Methods1992; 153: 79–83.
43.
SlaatsEHKennedyJCKruijswiljkH.Interference of sex-hormone binding globulin in the ‘Coat-A-Count’ testosterone no extraction radioimmunoassay. Clin Chem1987; 33: 300–2.
44.
MastersAMHahnelR.Investigation of sex-hormone binding globulin interference in direct radioimmunoassays for testosterone and estradiol. Clin Chem1989; 35: 979–84.
45.
BodlaenderP.No SHBG interference with the ‘Coat-A-Count’ total testosterone direct RIA kit. Clin Chem1990; 36: 173.
46.
LuppaPNeumeierD.Effect of sex hormone binding globulin on no-extraction immunoassays for testosterone. Clin Chem1990; 36: 172–3.
BartalanaLRobbinsJ.Thyroid hormone transport proteins. Clin Lab Med.1993; 13: 583–98.
49.
EkinsRP.Measurement of free hormones in blood. Endocr Rev.1990; 11: 5–46.
50.
NelsonJCWilcoxRB.Analytical performance of free and total thyroxine assays. Clin Chem1996; 42: 146–54.
51.
TuttlebeeJW.Further experience with free thyroxine assays with particular reference to pregnancy. Ann Clin Biochem1982; 19: 374–8.
52.
ReillyCPAdamekKJWellbyML.Critical assessment of the Amerlite free T4 assay. Ann Clin Biochem1989; 26: 517–21.
53.
AshwellKHoptonMRHarropJS.Serum free thyroxine concentrations in subjects with high circulating levels of thyroxine binding globulin. Ann Clin Biochem1983; 20: 285–8.
54.
NishikawaMOgawaYYoshikawaNYoshimuraMToyodaNShouzuAPlasma free thyroxine (free T4) concentrations during haemodialysis in patients with chronic renal failure: effects of non-esterified fatty acids on free T4 measurement. Endocr J1996; 43: 487–93.
55.
MidgleyJEMSheehanCPChristofidesNDFryJEBrowningDMardellR.Concentrations of free thyroxine and albumin in severe nonthyroidal illness: assay artefacts and physiological influences. Clin Chem1990; 36: 765–71.
56.
DocterRvan ToorHKrenningEPde JongMHennemanG.Free thyroxine assessed with three assays in sera of patients with non-thyroidal illness and of subjects with abnormal concentrations of thyroxine binding proteins. Clin Chem1993; 39: 1668–74.
57.
StockigtJRToplissDJBarlowJWWhiteELHurleyDMTaftP.Familial euthyroid thyroxine excess: an appropriate response to abnormal thyroxine binding associated with albumin. J Clin Endocrinol Metab1981; 53: 353–9.
58.
ScotolinniAGBhagavanNVOshiroTPowersL.Familial dysalbuminemic hyperthyroxinemia: a study of four probands and the kindred of three. Clin Chem1984; 30: 1179–81.
59.
HennemanGDocterRKrenningEPBosGOttenMVisserTJ.Raised total thyroxine and free thyroxine index but normal free thyroxine. A serum abnormality due to inherited increased affinity of iodothyronines for serum binding proteins. Lancet1979; 1: 639–42.
60.
StewartFMRatcliffeWARobertsI.Thyroid function tests in patients with familial dysalbuminaemic hyperthyroxinaemia (FDH). Ann Clin Biochem1986; 23: 59–64.
61.
RobbinsJRallJERawsonRW.An unusual instance of thyroxine-binding by human serum gamma globulin. J Clin Endocrinol Metab1956; 16: 573–9.
62.
SakataSMatsudaMOgawaTTakunoHMatsuiISaruiHPrevalence of thyroid hormone autoantibodies in healthy subjects. Clin Endocrinol1994; 41: 365–70.
63.
RitterDBrownWNahmMHLadensonJHScottMG.Endogenous serum antibodies that interfere with a common thyroid hormone uptake assay: characterisation and prevalence. Clin Chem1994; 40: 1940–3.
64.
ChristofedesNDSheehanCPMidgleyJEM.One-step, labelled antibody assay for measuring free thyroxin. I. Assay development and validation. Clin Chem1992; 38: 11–18.
65.
SheehanCPChristofedesND.One-step, labelled antibody assay for measuring free thyroxine II performance in a multicentre trial. Clin Chem1992; 38: 19–25.
66.
LaiLCDayJAClarkFPeastonRT.Spuriously high free thyroxine with the Amerlite MAB free T4 assay. J Clin Pathol1994; 47: 181–2.
67.
WesterhuisLWJJMVenekampWJJR.Falsely high free thyroxine concentration measured with Amerlite MAB free T4. Clin Chem1995; 41: 633–4.
68.
RitterDBrownWNahmMHLadensonJHScottMG.Endogenous serum antibodies that interfere with a common thyroid hormone uptake assay: characterisation and prevalence. Clin Chem1994; 40: 1940–3.
69.
SpencerCATakeuchiMKazarosyanM.Current status and performance goals for serum thyroglobulin assays. Clin Chem1996; 42: 164–73.
70.
Feldt-RasmussenU.Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin and thyrotropin receptor. Clin Chem1996; 42: 160–3.
71.
BoscatoLMStuartMC.Incidence and specificity of interference in two-site immunoassays. Clin Chem1986; 32: 1491–5.
KurokiMMatsumoYArakawaFHarunoMMurakamiMOzakiHReducing interference from heterophilic antibodies in a two-site immunoassay for carcino-embryonic antigen (CEA) by using a human mouse chimeric antibody to CEA as the tracer. J Immunol Methods1995; 180: 81–91.
74.
HansenHJLaFontaineGNewmanESSchwartzMKMalkinAMojsizikKSolving the problem of antibody interference in commercial ‘sandwich’-type immunoassays of carcinoembryonic antigen. Clin Chem1989; 35: 146–51.
75.
BoermanOCSegersMFGPoelsLGKenemansPThomasCMG.Heterophilic antibodies in human sera causing falsely increased results in the CA 125 immunofluorimetric assay. Clin Chem1990; 36: 888–91.
76.
ReinsbergJHeydweillerAWagnerUPfellKOehrPKrebsD.Evidence for interaction of human anti-idiotypic antibodies with CA 125 determination in a patient after radioimmunodetection. Clin Chem1990; 36: 164–7.
77.
KrickaLSchmerfeld-PrussSeniorMGoodmanDBPKaladasP.Interference by human anti-mouse antibody in two-site immunoassays. Clin Chem1990; 36: 892–4.
78.
FiadTMDuffyJMcKennaTJ.Multiple spuriously abnormal thyroid function indices due to heterophilic antibodies. Clin Endocrinol1994; 41: 391–5.
79.
LiendoCGhaliJKGravesSW.A new interference in some digoxin assays: anti-murine heterophilic antibodies. Clin Pharmacol Ther1996; 60: 593–8.
80.
JohnRHenleyRBarronN.Antibody interference in a two site immunometric assay for thyrotrophin. Ann Clin Biochem1989; 26: 346–52.
81.
MadryNAuerbachBSchelpC.Measures to overcome HAMA interferences in immunoassays. Anticancer Res.1997; 17: 2883–6.
82.
JagerWZollerO.Human anti-mouse antibodies against OC 125 do not interfere in a CA 125 assay that uses OC 125 and M11 antibodies. Clin Chem1993; 39: 1556–7.
83.
HasholznerUStieberPMeierWLamerzR.Value of HAMA — determination in clinical practice — an overview. Anticancer Res.1997; 17: 3055–8.
84.
LabusJMPetersenBH.Quantitation of human anti-mouse antibody by flow cytometry. Cytometry1992; 13: 275–81.
85.
BenvengaSCalziLLRobbinsJ.Effect of free fatty acids and nonlipid inhibitors of thyroid hormone binding in the immunoradiometric assay of thyroxine binding globulin. Clin Chem1987; 33: 1752–5.
86.
EzamEEmmanuelAValenteDGrognetJM.Effect of variability of plasma interferences on the accuracy of drug immunoassays. Ther Drug Monit1997; 19: 212–8.
87.
YunWSHoCSPanesarNSSwaminathanR.The contribution of steroids to digoxin-like immunoreactivity in cord blood. Ann Clin Biochem1992; 29: 337–42.
88.
FushimiRYamanishiHInoueMIyamaSAminoN.Digoxin immunoassay that avoids cross reactivity from Chinese medicines. Clin Chem1995; 41: 621.
89.
MilesLELipschitzDABeiberCPCookJD.Measurement of serum ferritin by a two-site immunoradiometric assay. Anal Biochem1974; 61: 209–24.
90.
RodbardDFeldmanYJaffeMLMilesLE.Kinetics of two-site immunoradiometric (sandwich) assays — II. Studies on the nature of the ‘high dose hook effect’. Immunochemistry1978; 15: 77–82.
91.
KileenAARameyMLDeanJJ.High dose hook effect in immunoluminmetric thyrotropin assay: the open-faced sandwich artefact. Ann Clin Biochem1993; 30: 413–4.
92.
PereraPWorwoodM.Antigen binding in the two-site immunoradiometric assay for serum ferritin: the nature of the hook effect. Ann Clin Biochem1984; 21: 393–7.
93.
RyallRGStoryCJTurnerDR.Reappraisal of the causes of the ‘hook effect’ in two-site immunoradiometric assays. Anal Biochem1982; 127: 308–15.
94.
FernandoSASportsmanJRWilsonGS.Studies of the low dose hook effect in a competitive homogeneous immunoassay. J Immunol Methods1992; 151: 27–46.
95.
FernandoSAWilsonGS.Studies of the hook effect in the one step sandwich immunoassay. J Immunol Methods1992; 151: 47–66.
96.
FernandoSAWilsonGS.Multiple epitope interactions in the two-step sandwich immunoassay. J Immunol Methods1992; 151: 67–86.
97.
HoffmanKLParsonsGHAllerdtLJBrooksJMMilesLE.Elimination of ‘hook-effect’ in two-site immunoradiometric assays by kinetic rate analysis. Clin Chem1984; 30: 1499–501.
98.
FrengenJNustadKSchmidRLindmoT.A sequential binding assay with a working range extending beyond seven orders of magnitude. J Immunol Methods1995; 178: 131–40.
99.
LandsteinerK.The Specificity of Serological Reactions. Boston: Harvard University Press, 1945.
100.
AbrahamGE.Characterisation of steroid antisera. In: CameronEHDHillierSGGriffithsK, eds. Steroid Immunoassay Fifth Tenovus Workshop. Alpha and Omega Publishing, 1975: 67–78.
101.
EkinsRP.Immunoassay design and optimisation. In: PriceCPNewmanDJ, eds. Principles and Practice of Immunoassay. New York: Stockton Press; 1991: 96–153.
102.
IsmailAAAstleyPBurrWACawoodMShortFWakelinKThe role of testosterone measurements in the investigation of androgen disorders. Ann Clin Biochem1986; 23: 113–34.
103.
HillRPHensonDBSelbyCSaihanEThompsonGA.Grossly elevated testosterone in three female patients: an assay artefact on the Bayer Immuno-1. In: Proceedings of the ACB National Meeting (Focus 98), Glasgow, 11–15 May 1998: Abstract 45.
104.
MicallefJVHayesMLatifAAhsanRSufiSB.Serum binding of steroid tracers and its possible effects on direct steroid immunoassay. Ann Clin Biochem1995; 32: 566–74.
105.
FuquaJSSherESMigeonCJBerkowtitzGD.Assay of plasma testosterone during the first six months of life: importance of chromatographic purification of steroids. Clin Chem1995; 41: 1146–9.
106.
WallaceAM.Analytical support for the detection and treatment of congenital adrenal hyperplasia. Ann Clin Biochem1995; 32: 9–27.
107.
JohnRKadurySWoodheadSJPritchardMH.Fenclofac and thyroid function tests. Ann Clin Biochem1983; 20: 381–2.
108.
SalwayJG, ed. Drug Interaction Handbook. London: Chapman and Hall, 1990.
109.
YoungDS.Effects of Drugs on Clinical Laboratory Tests, 4th edn.Washington DC: American Association for Clinical Chemistry, 1995.
110.
PerryBChapmanRSMcConwayMGGriffinDBeastallGH.Specificity of two-site immunometric assays. Ann Clin Biochem1991; 28: 83–6.
111.
MorrisonSLCanfieldSPorterSTanLKTaoMWimsLA.Production and characterisation of genetically engineered antibody molecules. Clin Chem1988; 34: 1668–75.
OlukogaAOMitchellRWaltonNRobertsonWRLaingI.Differences in serum luteinising hormone measurements by immunoradiometric assay induced by kinetic manipulation of assay conditions are dependent on the endocrine milieu of serum. Ann Clin Biochem1996; 33: 107–11.
114.
PettersonKSISoderholmJR.Individual differences in lutropin immunoreactivity revealed by monoclonal antibodies. Clin Chem1991; 37: 333–40.
115.
VermesIBonteHAVeerGvd SluijsSchoemakerJ.Interpretations of five monoclonal immunoassays of lutropin and follitropin: effects of normalisation with WHO standard. Clin Chem1991; 37: 415–21.
116.
DemersLM.Monoclonal antibodies to lutropin: are our immunoassays too specific?Clin Chem1991; 37: 311–2.
117.
FincoBBizzaroNScomparinD.Pitfalls in measuring lutropin by two-site immunoassay with monoclonal antibodies against the intact molecule. Clin Chem1992; 38: 2159–60.
118.
SmithKAMcConwayMGPerryBChapmanRSBeastallGH.Discrepancies in hFSH measurement by two site IRMA in the ovulatory phase of the menstrual cycle. Ann Clin Biochem1992; 29: 351–3.
119.
KardanaAColeLA.Polypeptide nicks cause erroneous results in assays of human chorionic gonadotrophin free β-subunit. Clin Chem1992; 38: 26–3.
120.
WoodPJ.The measurement of parathyroid hormone. Ann Clin Biochem1992; 29: 11–21.